Global Antihyperuricemic Agents Market Growth 2022-2028

1.1 Market Introduction

1.2 Years Considered

1.3 Research Objectives

1.4 Market Research Methodology

1.5 Research Process and Data Source

1.6 Economic Indicators

1.7 Currency Considered

2 Executive Summary

2.1 World Market Overview

2.1.1 Global Antihyperuricemic Agents Annual Sales 2017-2028

2.1.2 World Current & Future Analysis for Antihyperuricemic Agents by Geographic Region, 2017, 2022 & 2028

2.1.3 World Current & Future Analysis for Antihyperuricemic Agents by Country/Region, 2017, 2022 & 2028

2.2 Antihyperuricemic Agents Segment by Type

2.2.1 Inhibit Uric Acid Production Agents

2.2.2 Promote Uric Acid Excretion Agents

2.2.3 Others

2.3 Antihyperuricemic Agents Sales by Type

2.3.1 Global Antihyperuricemic Agents Sales Market Share by Type (2017-2022)

2.3.2 Global Antihyperuricemic Agents Revenue and Market Share by Type (2017-2022)

2.3.3 Global Antihyperuricemic Agents Sale Price by Type (2017-2022)

2.4 Antihyperuricemic Agents Segment by Distribution Channel

2.4.1 Hospital Pharmacies

2.4.2 Retail Pharmacies

2.4.3 Online Pharmacies

2.5 Antihyperuricemic Agents Sales by Distribution Channel

2.5.1 Global Antihyperuricemic Agents Sale Market Share by Distribution Channel (2017-2022)

2.5.2 Global Antihyperuricemic Agents Revenue and Market Share by Distribution Channel (2017-2022)

2.5.3 Global Antihyperuricemic Agents Sale Price by Distribution Channel (2017-2022)

3 Global Antihyperuricemic Agents by Company

3.1 Global Antihyperuricemic Agents Breakdown Data by Company

3.1.1 Global Antihyperuricemic Agents Annual Sales by Company (2020-2022)

3.1.2 Global Antihyperuricemic Agents Sales Market Share by Company (2020-2022)

3.2 Global Antihyperuricemic Agents Annual Revenue by Company (2020-2022)

3.2.1 Global Antihyperuricemic Agents Revenue by Company (2020-2022)

3.2.2 Global Antihyperuricemic Agents Revenue Market Share by Company (2020-2022)

3.3 Global Antihyperuricemic Agents Sale Price by Company

3.4 Key Manufacturers Antihyperuricemic Agents Producing Area Distribution, Sales Area, Product Type

3.4.1 Key Manufacturers Antihyperuricemic Agents Product Location Distribution

3.4.2 Players Antihyperuricemic Agents Products Offered

3.5 Market Concentration Rate Analysis

3.5.1 Competition Landscape Analysis

3.5.2 Concentration Ratio (CR3, CR5 and CR10) & (2020-2022)

3.6 New Products and Potential Entrants

3.7 Mergers & Acquisitions, Expansion

4 World Historic Review for Antihyperuricemic Agents by Geographic Region

4.1 World Historic Antihyperuricemic Agents Market Size by Geographic Region (2017-2022)

4.1.1 Global Antihyperuricemic Agents Annual Sales by Geographic Region (2017-2022)

4.1.2 Global Antihyperuricemic Agents Annual Revenue by Geographic Region

4.2 World Historic Antihyperuricemic Agents Market Size by Country/Region (2017-2022)

4.2.1 Global Antihyperuricemic Agents Annual Sales by Country/Region (2017-2022)

4.2.2 Global Antihyperuricemic Agents Annual Revenue by Country/Region

4.3 Americas Antihyperuricemic Agents Sales Growth

4.4 APAC Antihyperuricemic Agents Sales Growth

4.5 Europe Antihyperuricemic Agents Sales Growth

4.6 Middle East & Africa Antihyperuricemic Agents Sales Growth

5 Americas

5.1 Americas Antihyperuricemic Agents Sales by Country

5.1.1 Americas Antihyperuricemic Agents Sales by Country (2017-2022)

5.1.2 Americas Antihyperuricemic Agents Revenue by Country (2017-2022)

5.2 Americas Antihyperuricemic Agents Sales by Type

5.3 Americas Antihyperuricemic Agents Sales by Distribution Channel

5.4 United States

5.5 Canada

5.6 Mexico

5.7 Brazil

6 APAC

6.1 APAC Antihyperuricemic Agents Sales by Region

6.1.1 APAC Antihyperuricemic Agents Sales by Region (2017-2022)

6.1.2 APAC Antihyperuricemic Agents Revenue by Region (2017-2022)

6.2 APAC Antihyperuricemic Agents Sales by Type

6.3 APAC Antihyperuricemic Agents Sales by Distribution Channel

6.4 China

6.5 Japan

6.6 South Korea

6.7 Southeast Asia

6.8 India

6.9 Australia

6.10 China Taiwan

7 Europe

7.1 Europe Antihyperuricemic Agents by Country

7.1.1 Europe Antihyperuricemic Agents Sales by Country (2017-2022)

7.1.2 Europe Antihyperuricemic Agents Revenue by Country (2017-2022)

7.2 Europe Antihyperuricemic Agents Sales by Type

7.3 Europe Antihyperuricemic Agents Sales by Distribution Channel

7.4 Germany

7.5 France

7.6 UK

7.7 Italy

7.8 Russia

8 Middle East & Africa

8.1 Middle East & Africa Antihyperuricemic Agents by Country

8.1.1 Middle East & Africa Antihyperuricemic Agents Sales by Country (2017-2022)

8.1.2 Middle East & Africa Antihyperuricemic Agents Revenue by Country (2017-2022)

8.2 Middle East & Africa Antihyperuricemic Agents Sales by Type

8.3 Middle East & Africa Antihyperuricemic Agents Sales by Distribution Channel

8.4 Egypt

8.5 South Africa

8.6 Israel

8.7 Turkey

8.8 GCC Countries

9 Market Drivers, Challenges and Trends

9.1 Market Drivers & Growth Opportunities

9.2 Market Challenges & Risks

9.3 Industry Trends

10 Manufacturing Cost Structure Analysis

10.1 Raw Material and Suppliers

10.2 Manufacturing Cost Structure Analysis of Antihyperuricemic Agents

10.3 Manufacturing Process Analysis of Antihyperuricemic Agents

10.4 Industry Chain Structure of Antihyperuricemic Agents

11 Marketing, Distributors and Customer

11.1 Sales Channel

11.1.1 Direct Channels

11.1.2 Indirect Channels

11.2 Antihyperuricemic Agents Distributors

11.3 Antihyperuricemic Agents Customer

12 World Forecast Review for Antihyperuricemic Agents by Geographic Region

12.1 Global Antihyperuricemic Agents Market Size Forecast by Region

12.1.1 Global Antihyperuricemic Agents Forecast by Region (2023-2028)

12.1.2 Global Antihyperuricemic Agents Annual Revenue Forecast by Region (2023-2028)

12.2 Americas Forecast by Country

12.3 APAC Forecast by Region

12.4 Europe Forecast by Country

12.5 Middle East & Africa Forecast by Country

12.6 Global Antihyperuricemic Agents Forecast by Type

12.7 Global Antihyperuricemic Agents Forecast by Distribution Channel

13 Key Players Analysis

13.1 Takeda Pharmaceuticals

13.1.1 Takeda Pharmaceuticals Company Information

13.1.2 Takeda Pharmaceuticals Antihyperuricemic Agents Product Offered

13.1.3 Takeda Pharmaceuticals Antihyperuricemic Agents Sales, Revenue, Price and Gross Margin (2020-2022)

13.1.4 Takeda Pharmaceuticals Main Business Overview

13.1.5 Takeda Pharmaceuticals Latest Developments

13.2 Hikma

13.2.1 Hikma Company Information

13.2.2 Hikma Antihyperuricemic Agents Product Offered

13.2.3 Hikma Antihyperuricemic Agents Sales, Revenue, Price and Gross Margin (2020-2022)

13.2.4 Hikma Main Business Overview

13.2.5 Hikma Latest Developments

13.3 Wockhardt

13.3.1 Wockhardt Company Information

13.3.2 Wockhardt Antihyperuricemic Agents Product Offered

13.3.3 Wockhardt Antihyperuricemic Agents Sales, Revenue, Price and Gross Margin (2020-2022)

13.3.4 Wockhardt Main Business Overview

13.3.5 Wockhardt Latest Developments

13.4 West Ward Pharmaceuticals

13.4.1 West Ward Pharmaceuticals Company Information

13.4.2 West Ward Pharmaceuticals Antihyperuricemic Agents Product Offered

13.4.3 West Ward Pharmaceuticals Antihyperuricemic Agents Sales, Revenue, Price and Gross Margin (2020-2022)

13.4.4 West Ward Pharmaceuticals Main Business Overview

13.4.5 West Ward Pharmaceuticals Latest Developments

13.5 Rhea Pharmaceutical

13.5.1 Rhea Pharmaceutical Company Information

13.5.2 Rhea Pharmaceutical Antihyperuricemic Agents Product Offered

13.5.3 Rhea Pharmaceutical Antihyperuricemic Agents Sales, Revenue, Price and Gross Margin (2020-2022)

13.5.4 Rhea Pharmaceutical Main Business Overview

13.5.5 Rhea Pharmaceutical Latest Developments

13.6 Medinova

13.6.1 Medinova Company Information

13.6.2 Medinova Antihyperuricemic Agents Product Offered

13.6.3 Medinova Antihyperuricemic Agents Sales, Revenue, Price and Gross Margin (2020-2022)

13.6.4 Medinova Main Business Overview

13.6.5 Medinova Latest Developments

13.7 Odan Laboratories

13.7.1 Odan Laboratories Company Information

13.7.2 Odan Laboratories Antihyperuricemic Agents Product Offered

13.7.3 Odan Laboratories Antihyperuricemic Agents Sales, Revenue, Price and Gross Margin (2020-2022)

13.7.4 Odan Laboratories Main Business Overview

13.7.5 Odan Laboratories Latest Developments

13.8 TEIJIN

13.8.1 TEIJIN Company Information

13.8.2 TEIJIN Antihyperuricemic Agents Product Offered

13.8.3 TEIJIN Antihyperuricemic Agents Sales, Revenue, Price and Gross Margin (2020-2022)

13.8.4 TEIJIN Main Business Overview

13.8.5 TEIJIN Latest Developments

13.9 Casper Pharma

13.9.1 Casper Pharma Company Information

13.9.2 Casper Pharma Antihyperuricemic Agents Product Offered

13.9.3 Casper Pharma Antihyperuricemic Agents Sales, Revenue, Price and Gross Margin (2020-2022)

13.9.4 Casper Pharma Main Business Overview

13.9.5 Casper Pharma Latest Developments

13.10 Dr. Reddys Laboratories

13.10.1 Dr. Reddys Laboratories Company Information

13.10.2 Dr. Reddys Laboratories Antihyperuricemic Agents Product Offered

13.10.3 Dr. Reddys Laboratories Antihyperuricemic Agents Sales, Revenue, Price and Gross Margin (2020-2022)

13.10.4 Dr. Reddys Laboratories Main Business Overview

13.10.5 Dr. Reddys Laboratories Latest Developments

13.11 Teva

13.11.1 Teva Company Information

13.11.2 Teva Antihyperuricemic Agents Product Offered

13.11.3 Teva Antihyperuricemic Agents Sales, Revenue, Price and Gross Margin (2020-2022)

13.11.4 Teva Main Business Overview

13.11.5 Teva Latest Developments

13.12 Zydus Pharmaceuticals

13.12.1 Zydus Pharmaceuticals Company Information

13.12.2 Zydus Pharmaceuticals Antihyperuricemic Agents Product Offered

13.12.3 Zydus Pharmaceuticals Antihyperuricemic Agents Sales, Revenue, Price and Gross Margin (2020-2022)

13.12.4 Zydus Pharmaceuticals Main Business Overview

13.12.5 Zydus Pharmaceuticals Latest Developments

13.13 Mylan

13.13.1 Mylan Company Information

13.13.2 Mylan Antihyperuricemic Agents Product Offered

13.13.3 Mylan Antihyperuricemic Agents Sales, Revenue, Price and Gross Margin (2020-2022)

13.13.4 Mylan Main Business Overview

13.13.5 Mylan Latest Developments

13.14 Sun Pharmaceutical

13.14.1 Sun Pharmaceutical Company Information

13.14.2 Sun Pharmaceutical Antihyperuricemic Agents Product Offered

13.14.3 Sun Pharmaceutical Antihyperuricemic Agents Sales, Revenue, Price and Gross Margin (2020-2022)

13.14.4 Sun Pharmaceutical Main Business Overview

13.14.5 Sun Pharmaceutical Latest Developments

13.15 APOTEX

13.15.1 APOTEX Company Information

13.15.2 APOTEX Antihyperuricemic Agents Product Offered

13.15.3 APOTEX Antihyperuricemic Agents Sales, Revenue, Price and Gross Margin (2020-2022)

13.15.4 APOTEX Main Business Overview

13.15.5 APOTEX Latest Developments

13.16 NorthStar Healthcare

13.16.1 NorthStar Healthcare Company Information

13.16.2 NorthStar Healthcare Antihyperuricemic Agents Product Offered

13.16.3 NorthStar Healthcare Antihyperuricemic Agents Sales, Revenue, Price and Gross Margin (2020-2022)

13.16.4 NorthStar Healthcare Main Business Overview

13.16.5 NorthStar Healthcare Latest Developments

13.17 Ipca Laboratories

13.17.1 Ipca Laboratories Company Information

13.17.2 Ipca Laboratories Antihyperuricemic Agents Product Offered

13.17.3 Ipca Laboratories Antihyperuricemic Agents Sales, Revenue, Price and Gross Margin (2020-2022)

13.17.4 Ipca Laboratories Main Business Overview

13.17.5 Ipca Laboratories Latest Developments

13.18 Accord Healthcare

13.18.1 Accord Healthcare Company Information

13.18.2 Accord Healthcare Antihyperuricemic Agents Product Offered

13.18.3 Accord Healthcare Antihyperuricemic Agents Sales, Revenue, Price and Gross Margin (2020-2022)

13.18.4 Accord Healthcare Main Business Overview

13.18.5 Accord Healthcare Latest Developments

13.19 Gentec Pharmaceutical Group

13.19.1 Gentec Pharmaceutical Group Company Information

13.19.2 Gentec Pharmaceutical Group Antihyperuricemic Agents Product Offered

13.19.3 Gentec Pharmaceutical Group Antihyperuricemic Agents Sales, Revenue, Price and Gross Margin (2020-2022)

13.19.4 Gentec Pharmaceutical Group Main Business Overview

13.19.5 Gentec Pharmaceutical Group Latest Developments

13.20 Indoco Remedies

13.20.1 Indoco Remedies Company Information

13.20.2 Indoco Remedies Antihyperuricemic Agents Product Offered

13.20.3 Indoco Remedies Antihyperuricemic Agents Sales, Revenue, Price and Gross Margin (2020-2022)

13.20.4 Indoco Remedies Main Business Overview

13.20.5 Indoco Remedies Latest Developments

13.21 Lupin

13.21.1 Lupin Company Information

13.21.2 Lupin Antihyperuricemic Agents Product Offered

13.21.3 Lupin Antihyperuricemic Agents Sales, Revenue, Price and Gross Margin (2020-2022)

13.21.4 Lupin Main Business Overview

13.21.5 Lupin Latest Developments

13.22 Waterstone Pharmaceuticals

13.22.1 Waterstone Pharmaceuticals Company Information

13.22.2 Waterstone Pharmaceuticals Antihyperuricemic Agents Product Offered

13.22.3 Waterstone Pharmaceuticals Antihyperuricemic Agents Sales, Revenue, Price and Gross Margin (2020-2022)

13.22.4 Waterstone Pharmaceuticals Main Business Overview

13.22.5 Waterstone Pharmaceuticals Latest Developments

13.23 ALP Pharm

13.23.1 ALP Pharm Company Information

13.23.2 ALP Pharm Antihyperuricemic Agents Product Offered

13.23.3 ALP Pharm Antihyperuricemic Agents Sales, Revenue, Price and Gross Margin (2020-2022)

13.23.4 ALP Pharm Main Business Overview

13.23.5 ALP Pharm Latest Developments

13.24 Jiangsu Hengrui Medicine

13.24.1 Jiangsu Hengrui Medicine Company Information

13.24.2 Jiangsu Hengrui Medicine Antihyperuricemic Agents Product Offered

13.24.3 Jiangsu Hengrui Medicine Antihyperuricemic Agents Sales, Revenue, Price and Gross Margin (2020-2022)

13.24.4 Jiangsu Hengrui Medicine Main Business Overview

13.24.5 Jiangsu Hengrui Medicine Latest Developments

13.25 Jiangsu Wanbang Biopharmaceuticals

13.25.1 Jiangsu Wanbang Biopharmaceuticals Company Information

13.25.2 Jiangsu Wanbang Biopharmaceuticals Antihyperuricemic Agents Product Offered

13.25.3 Jiangsu Wanbang Biopharmaceuticals Antihyperuricemic Agents Sales, Revenue, Price and Gross Margin (2020-2022)

13.25.4 Jiangsu Wanbang Biopharmaceuticals Main Business Overview

13.25.5 Jiangsu Wanbang Biopharmaceuticals Latest Developments

13.26 Hangzhou Zhuyangxin Pharmaceutical

13.26.1 Hangzhou Zhuyangxin Pharmaceutical Company Information

13.26.2 Hangzhou Zhuyangxin Pharmaceutical Antihyperuricemic Agents Product Offered

13.26.3 Hangzhou Zhuyangxin Pharmaceutical Antihyperuricemic Agents Sales, Revenue, Price and Gross Margin (2020-2022)

13.26.4 Hangzhou Zhuyangxin Pharmaceutical Main Business Overview

13.26.5 Hangzhou Zhuyangxin Pharmaceutical Latest Developments

13.27 YiChang HEC ChangJiang Pharmaceutical

13.27.1 YiChang HEC ChangJiang Pharmaceutical Company Information

13.27.2 YiChang HEC ChangJiang Pharmaceutical Antihyperuricemic Agents Product Offered

13.27.3 YiChang HEC ChangJiang Pharmaceutical Antihyperuricemic Agents Sales, Revenue, Price and Gross Margin (2020-2022)

13.27.4 YiChang HEC ChangJiang Pharmaceutical Main Business Overview

13.27.5 YiChang HEC ChangJiang Pharmaceutical Latest Developments

13.28 KPC Pharmaceuticals

13.28.1 KPC Pharmaceuticals Company Information

13.28.2 KPC Pharmaceuticals Antihyperuricemic Agents Product Offered

13.28.3 KPC Pharmaceuticals Antihyperuricemic Agents Sales, Revenue, Price and Gross Margin (2020-2022)

13.28.4 KPC Pharmaceuticals Main Business Overview

13.28.5 KPC Pharmaceuticals Latest Developments

13.29 Tonghua Limin

13.29.1 Tonghua Limin Company Information

13.29.2 Tonghua Limin Antihyperuricemic Agents Product Offered

13.29.3 Tonghua Limin Antihyperuricemic Agents Sales, Revenue, Price and Gross Margin (2020-2022)

13.29.4 Tonghua Limin Main Business Overview

13.29.5 Tonghua Limin Latest Developments

13.30 Beijing Jialin Pharmaceutical

13.30.1 Beijing Jialin Pharmaceutical Company Information

13.30.2 Beijing Jialin Pharmaceutical Antihyperuricemic Agents Product Offered

13.30.3 Beijing Jialin Pharmaceutical Antihyperuricemic Agents Sales, Revenue, Price and Gross Margin (2020-2022)

13.30.4 Beijing Jialin Pharmaceutical Main Business Overview

13.30.5 Beijing Jialin Pharmaceutical Latest Developments

14 Research Findings and Conclusion

Table 1. Antihyperuricemic Agents Annual Sales CAGR by Geographic Region (2017, 2022 & 2028) & ($ millions)

Table 2. Antihyperuricemic Agents Annual Sales CAGR by Country/Region (2017, 2022 & 2028) & ($ millions)

Table 3. Major Players of Inhibit Uric Acid Production Agents

Table 4. Major Players of Promote Uric Acid Excretion Agents

Table 5. Major Players of Others

Table 6. Global Antihyperuricemic Agents Sales by Type (2017-2022) & (K Units)

Table 7. Global Antihyperuricemic Agents Sales Market Share by Type (2017-2022)

Table 8. Global Antihyperuricemic Agents Revenue by Type (2017-2022) & ($ million)

Table 9. Global Antihyperuricemic Agents Revenue Market Share by Type (2017-2022)

Table 10. Global Antihyperuricemic Agents Sale Price by Type (2017-2022) & (US$/Unit)

Table 11. Global Antihyperuricemic Agents Sales by Distribution Channel (2017-2022) & (K Units)

Table 12. Global Antihyperuricemic Agents Sales Market Share by Distribution Channel (2017-2022)

Table 13. Global Antihyperuricemic Agents Revenue by Distribution Channel (2017-2022)

Table 14. Global Antihyperuricemic Agents Revenue Market Share by Distribution Channel (2017-2022)

Table 15. Global Antihyperuricemic Agents Sale Price by Distribution Channel (2017-2022) & (US$/Unit)

Table 16. Global Antihyperuricemic Agents Sales by Company (2020-2022) & (K Units)

Table 17. Global Antihyperuricemic Agents Sales Market Share by Company (2020-2022)

Table 18. Global Antihyperuricemic Agents Revenue by Company (2020-2022) ($ Millions)

Table 19. Global Antihyperuricemic Agents Revenue Market Share by Company (2020-2022)

Table 20. Global Antihyperuricemic Agents Sale Price by Company (2020-2022) & (US$/Unit)

Table 21. Key Manufacturers Antihyperuricemic Agents Producing Area Distribution and Sales Area

Table 22. Players Antihyperuricemic Agents Products Offered

Table 23. Antihyperuricemic Agents Concentration Ratio (CR3, CR5 and CR10) & (2020-2022)

Table 24. New Products and Potential Entrants

Table 25. Mergers & Acquisitions, Expansion

Table 26. Global Antihyperuricemic Agents Sales by Geographic Region (2017-2022) & (K Units)

Table 27. Global Antihyperuricemic Agents Sales Market Share Geographic Region (2017-2022)

Table 28. Global Antihyperuricemic Agents Revenue by Geographic Region (2017-2022) & ($ millions)

Table 29. Global Antihyperuricemic Agents Revenue Market Share by Geographic Region (2017-2022)

Table 30. Global Antihyperuricemic Agents Sales by Country/Region (2017-2022) & (K Units)

Table 31. Global Antihyperuricemic Agents Sales Market Share by Country/Region (2017-2022)

Table 32. Global Antihyperuricemic Agents Revenue by Country/Region (2017-2022) & ($ millions)

Table 33. Global Antihyperuricemic Agents Revenue Market Share by Country/Region (2017-2022)

Table 34. Americas Antihyperuricemic Agents Sales by Country (2017-2022) & (K Units)

Table 35. Americas Antihyperuricemic Agents Sales Market Share by Country (2017-2022)

Table 36. Americas Antihyperuricemic Agents Revenue by Country (2017-2022) & ($ Millions)

Table 37. Americas Antihyperuricemic Agents Revenue Market Share by Country (2017-2022)

Table 38. Americas Antihyperuricemic Agents Sales by Type (2017-2022) & (K Units)

Table 39. Americas Antihyperuricemic Agents Sales Market Share by Type (2017-2022)

Table 40. Americas Antihyperuricemic Agents Sales by Distribution Channel (2017-2022) & (K Units)

Table 41. Americas Antihyperuricemic Agents Sales Market Share by Distribution Channel (2017-2022)

Table 42. APAC Antihyperuricemic Agents Sales by Region (2017-2022) & (K Units)

Table 43. APAC Antihyperuricemic Agents Sales Market Share by Region (2017-2022)

Table 44. APAC Antihyperuricemic Agents Revenue by Region (2017-2022) & ($ Millions)

Table 45. APAC Antihyperuricemic Agents Revenue Market Share by Region (2017-2022)

Table 46. APAC Antihyperuricemic Agents Sales by Type (2017-2022) & (K Units)

Table 47. APAC Antihyperuricemic Agents Sales Market Share by Type (2017-2022)

Table 48. APAC Antihyperuricemic Agents Sales by Distribution Channel (2017-2022) & (K Units)

Table 49. APAC Antihyperuricemic Agents Sales Market Share by Distribution Channel (2017-2022)

Table 50. Europe Antihyperuricemic Agents Sales by Country (2017-2022) & (K Units)

Table 51. Europe Antihyperuricemic Agents Sales Market Share by Country (2017-2022)

Table 52. Europe Antihyperuricemic Agents Revenue by Country (2017-2022) & ($ Millions)

Table 53. Europe Antihyperuricemic Agents Revenue Market Share by Country (2017-2022)

Table 54. Europe Antihyperuricemic Agents Sales by Type (2017-2022) & (K Units)

Table 55. Europe Antihyperuricemic Agents Sales Market Share by Type (2017-2022)

Table 56. Europe Antihyperuricemic Agents Sales by Distribution Channel (2017-2022) & (K Units)

Table 57. Europe Antihyperuricemic Agents Sales Market Share by Distribution Channel (2017-2022)

Table 58. Middle East & Africa Antihyperuricemic Agents Sales by Country (2017-2022) & (K Units)

Table 59. Middle East & Africa Antihyperuricemic Agents Sales Market Share by Country (2017-2022)

Table 60. Middle East & Africa Antihyperuricemic Agents Revenue by Country (2017-2022) & ($ Millions)

Table 61. Middle East & Africa Antihyperuricemic Agents Revenue Market Share by Country (2017-2022)

Table 62. Middle East & Africa Antihyperuricemic Agents Sales by Type (2017-2022) & (K Units)

Table 63. Middle East & Africa Antihyperuricemic Agents Sales Market Share by Type (2017-2022)

Table 64. Middle East & Africa Antihyperuricemic Agents Sales by Distribution Channel (2017-2022) & (K Units)

Table 65. Middle East & Africa Antihyperuricemic Agents Sales Market Share by Distribution Channel (2017-2022)

Table 66. Key Market Drivers & Growth Opportunities of Antihyperuricemic Agents

Table 67. Key Market Challenges & Risks of Antihyperuricemic Agents

Table 68. Key Industry Trends of Antihyperuricemic Agents

Table 69. Antihyperuricemic Agents Raw Material

Table 70. Key Suppliers of Raw Materials

Table 71. Antihyperuricemic Agents Distributors List

Table 72. Antihyperuricemic Agents Customer List

Table 73. Global Antihyperuricemic Agents Sales Forecast by Region (2023-2028) & (K Units)

Table 74. Global Antihyperuricemic Agents Sales Market Forecast by Region

Table 75. Global Antihyperuricemic Agents Revenue Forecast by Region (2023-2028) & ($ millions)

Table 76. Global Antihyperuricemic Agents Revenue Market Share Forecast by Region (2023-2028)

Table 77. Americas Antihyperuricemic Agents Sales Forecast by Country (2023-2028) & (K Units)

Table 78. Americas Antihyperuricemic Agents Revenue Forecast by Country (2023-2028) & ($ millions)

Table 79. APAC Antihyperuricemic Agents Sales Forecast by Region (2023-2028) & (K Units)

Table 80. APAC Antihyperuricemic Agents Revenue Forecast by Region (2023-2028) & ($ millions)

Table 81. Europe Antihyperuricemic Agents Sales Forecast by Country (2023-2028) & (K Units)

Table 82. Europe Antihyperuricemic Agents Revenue Forecast by Country (2023-2028) & ($ millions)

Table 83. Middle East & Africa Antihyperuricemic Agents Sales Forecast by Country (2023-2028) & (K Units)

Table 84. Middle East & Africa Antihyperuricemic Agents Revenue Forecast by Country (2023-2028) & ($ millions)

Table 85. Global Antihyperuricemic Agents Sales Forecast by Type (2023-2028) & (K Units)

Table 86. Global Antihyperuricemic Agents Sales Market Share Forecast by Type (2023-2028)

Table 87. Global Antihyperuricemic Agents Revenue Forecast by Type (2023-2028) & ($ Millions)

Table 88. Global Antihyperuricemic Agents Revenue Market Share Forecast by Type (2023-2028)

Table 89. Global Antihyperuricemic Agents Sales Forecast by Distribution Channel (2023-2028) & (K Units)

Table 90. Global Antihyperuricemic Agents Sales Market Share Forecast by Distribution Channel (2023-2028)

Table 91. Global Antihyperuricemic Agents Revenue Forecast by Distribution Channel (2023-2028) & ($ Millions)

Table 92. Global Antihyperuricemic Agents Revenue Market Share Forecast by Distribution Channel (2023-2028)

Table 93. Takeda Pharmaceuticals Basic Information, Antihyperuricemic Agents Manufacturing Base, Sales Area and Its Competitors

Table 94. Takeda Pharmaceuticals Antihyperuricemic Agents Product Offered

Table 95. Takeda Pharmaceuticals Antihyperuricemic Agents Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2020-2022)

Table 96. Takeda Pharmaceuticals Main Business

Table 97. Takeda Pharmaceuticals Latest Developments

Table 98. Hikma Basic Information, Antihyperuricemic Agents Manufacturing Base, Sales Area and Its Competitors

Table 99. Hikma Antihyperuricemic Agents Product Offered

Table 100. Hikma Antihyperuricemic Agents Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2020-2022)

Table 101. Hikma Main Business

Table 102. Hikma Latest Developments

Table 103. Wockhardt Basic Information, Antihyperuricemic Agents Manufacturing Base, Sales Area and Its Competitors

Table 104. Wockhardt Antihyperuricemic Agents Product Offered

Table 105. Wockhardt Antihyperuricemic Agents Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2020-2022)

Table 106. Wockhardt Main Business

Table 107. Wockhardt Latest Developments

Table 108. West Ward Pharmaceuticals Basic Information, Antihyperuricemic Agents Manufacturing Base, Sales Area and Its Competitors

Table 109. West Ward Pharmaceuticals Antihyperuricemic Agents Product Offered

Table 110. West Ward Pharmaceuticals Antihyperuricemic Agents Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2020-2022)

Table 111. West Ward Pharmaceuticals Main Business

Table 112. West Ward Pharmaceuticals Latest Developments

Table 113. Rhea Pharmaceutical Basic Information, Antihyperuricemic Agents Manufacturing Base, Sales Area and Its Competitors

Table 114. Rhea Pharmaceutical Antihyperuricemic Agents Product Offered

Table 115. Rhea Pharmaceutical Antihyperuricemic Agents Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2020-2022)

Table 116. Rhea Pharmaceutical Main Business

Table 117. Rhea Pharmaceutical Latest Developments

Table 118. Medinova Basic Information, Antihyperuricemic Agents Manufacturing Base, Sales Area and Its Competitors

Table 119. Medinova Antihyperuricemic Agents Product Offered

Table 120. Medinova Antihyperuricemic Agents Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2020-2022)

Table 121. Medinova Main Business

Table 122. Medinova Latest Developments

Table 123. Odan Laboratories Basic Information, Antihyperuricemic Agents Manufacturing Base, Sales Area and Its Competitors

Table 124. Odan Laboratories Antihyperuricemic Agents Product Offered

Table 125. Odan Laboratories Antihyperuricemic Agents Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2020-2022)

Table 126. Odan Laboratories Main Business

Table 127. Odan Laboratories Latest Developments

Table 128. TEIJIN Basic Information, Antihyperuricemic Agents Manufacturing Base, Sales Area and Its Competitors

Table 129. TEIJIN Antihyperuricemic Agents Product Offered

Table 130. TEIJIN Antihyperuricemic Agents Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2020-2022)

Table 131. TEIJIN Main Business

Table 132. TEIJIN Latest Developments

Table 133. Casper Pharma Basic Information, Antihyperuricemic Agents Manufacturing Base, Sales Area and Its Competitors

Table 134. Casper Pharma Antihyperuricemic Agents Product Offered

Table 135. Casper Pharma Antihyperuricemic Agents Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2020-2022)

Table 136. Casper Pharma Main Business

Table 137. Casper Pharma Latest Developments

Table 138. Dr. Reddys Laboratories Basic Information, Antihyperuricemic Agents Manufacturing Base, Sales Area and Its Competitors

Table 139. Dr. Reddys Laboratories Antihyperuricemic Agents Product Offered

Table 140. Dr. Reddys Laboratories Antihyperuricemic Agents Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2020-2022)

Table 141. Dr. Reddys Laboratories Main Business

Table 142. Dr. Reddys Laboratories Latest Developments

Table 143. Teva Basic Information, Antihyperuricemic Agents Manufacturing Base, Sales Area and Its Competitors

Table 144. Teva Antihyperuricemic Agents Product Offered

Table 145. Teva Antihyperuricemic Agents Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2020-2022)

Table 146. Teva Main Business

Table 147. Teva Latest Developments

Table 148. Zydus Pharmaceuticals Basic Information, Antihyperuricemic Agents Manufacturing Base, Sales Area and Its Competitors

Table 149. Zydus Pharmaceuticals Antihyperuricemic Agents Product Offered

Table 150. Zydus Pharmaceuticals Antihyperuricemic Agents Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2020-2022)

Table 151. Zydus Pharmaceuticals Main Business

Table 152. Zydus Pharmaceuticals Latest Developments

Table 153. Mylan Basic Information, Antihyperuricemic Agents Manufacturing Base, Sales Area and Its Competitors

Table 154. Mylan Antihyperuricemic Agents Product Offered

Table 155. Mylan Antihyperuricemic Agents Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2020-2022)

Table 156. Mylan Main Business

Table 157. Mylan Latest Developments

Table 158. Sun Pharmaceutical Basic Information, Antihyperuricemic Agents Manufacturing Base, Sales Area and Its Competitors

Table 159. Sun Pharmaceutical Antihyperuricemic Agents Product Offered

Table 160. Sun Pharmaceutical Antihyperuricemic Agents Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2020-2022)

Table 161. Sun Pharmaceutical Main Business

Table 162. Sun Pharmaceutical Latest Developments

Table 163. APOTEX Basic Information, Antihyperuricemic Agents Manufacturing Base, Sales Area and Its Competitors

Table 164. APOTEX Antihyperuricemic Agents Product Offered

Table 165. APOTEX Antihyperuricemic Agents Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2020-2022)

Table 166. APOTEX Main Business

Table 167. APOTEX Latest Developments

Table 168. NorthStar Healthcare Basic Information, Antihyperuricemic Agents Manufacturing Base, Sales Area and Its Competitors

Table 169. NorthStar Healthcare Antihyperuricemic Agents Product Offered

Table 170. NorthStar Healthcare Antihyperuricemic Agents Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2020-2022)

Table 171. NorthStar Healthcare Main Business

Table 172. NorthStar Healthcare Latest Developments

Table 173. Ipca Laboratories Basic Information, Antihyperuricemic Agents Manufacturing Base, Sales Area and Its Competitors

Table 174. Ipca Laboratories Antihyperuricemic Agents Product Offered

Table 175. Ipca Laboratories Antihyperuricemic Agents Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2020-2022)

Table 176. Ipca Laboratories Main Business

Table 177. Ipca Laboratories Latest Developments

Table 178. Accord Healthcare Basic Information, Antihyperuricemic Agents Manufacturing Base, Sales Area and Its Competitors

Table 179. Accord Healthcare Antihyperuricemic Agents Product Offered

Table 180. Accord Healthcare Antihyperuricemic Agents Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2020-2022)

Table 181. Accord Healthcare Main Business

Table 182. Accord Healthcare Latest Developments

Table 183. Gentec Pharmaceutical Group Basic Information, Antihyperuricemic Agents Manufacturing Base, Sales Area and Its Competitors

Table 184. Gentec Pharmaceutical Group Antihyperuricemic Agents Product Offered

Table 185. Gentec Pharmaceutical Group Antihyperuricemic Agents Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2020-2022)

Table 186. Gentec Pharmaceutical Group Main Business

Table 187. Gentec Pharmaceutical Group Latest Developments

Table 188. Indoco Remedies Basic Information, Antihyperuricemic Agents Manufacturing Base, Sales Area and Its Competitors

Table 189. Indoco Remedies Antihyperuricemic Agents Product Offered

Table 190. Indoco Remedies Antihyperuricemic Agents Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2020-2022)

Table 191. Indoco Remedies Main Business

Table 192. Indoco Remedies Latest Developments

Table 193. Lupin Basic Information, Antihyperuricemic Agents Manufacturing Base, Sales Area and Its Competitors

Table 194. Lupin Antihyperuricemic Agents Product Offered

Table 195. Lupin Antihyperuricemic Agents Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2020-2022)

Table 196. Lupin Main Business

Table 197. Lupin Latest Developments

Table 198. Waterstone Pharmaceuticals Basic Information, Antihyperuricemic Agents Manufacturing Base, Sales Area and Its Competitors

Table 199. Waterstone Pharmaceuticals Antihyperuricemic Agents Product Offered

Table 200. Waterstone Pharmaceuticals Antihyperuricemic Agents Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2020-2022)

Table 201. Waterstone Pharmaceuticals Main Business

Table 202. Waterstone Pharmaceuticals Latest Developments

Table 203. ALP Pharm Basic Information, Antihyperuricemic Agents Manufacturing Base, Sales Area and Its Competitors

Table 204. ALP Pharm Antihyperuricemic Agents Product Offered

Table 205. ALP Pharm Antihyperuricemic Agents Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2020-2022)

Table 206. ALP Pharm Main Business

Table 207. ALP Pharm Latest Developments

Table 208. Jiangsu Hengrui Medicine Basic Information, Antihyperuricemic Agents Manufacturing Base, Sales Area and Its Competitors

Table 209. Jiangsu Hengrui Medicine Antihyperuricemic Agents Product Offered

Table 210. Jiangsu Hengrui Medicine Antihyperuricemic Agents Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2020-2022)

Table 211. Jiangsu Hengrui Medicine Main Business

Table 212. Jiangsu Hengrui Medicine Latest Developments

Table 213. Jiangsu Wanbang Biopharmaceuticals Basic Information, Antihyperuricemic Agents Manufacturing Base, Sales Area and Its Competitors

Table 214. Jiangsu Wanbang Biopharmaceuticals Antihyperuricemic Agents Product Offered

Table 215. Jiangsu Wanbang Biopharmaceuticals Antihyperuricemic Agents Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2020-2022)

Table 216. Jiangsu Wanbang Biopharmaceuticals Main Business

Table 217. Jiangsu Wanbang Biopharmaceuticals Latest Developments

Table 218. Hangzhou Zhuyangxin Pharmaceutical Basic Information, Antihyperuricemic Agents Manufacturing Base, Sales Area and Its Competitors

Table 219. Hangzhou Zhuyangxin Pharmaceutical Antihyperuricemic Agents Product Offered

Table 220. Hangzhou Zhuyangxin Pharmaceutical Antihyperuricemic Agents Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2020-2022)

Table 221. Hangzhou Zhuyangxin Pharmaceutical Main Business

Table 222. Hangzhou Zhuyangxin Pharmaceutical Latest Developments

Table 223. YiChang HEC ChangJiang Pharmaceutical Basic Information, Antihyperuricemic Agents Manufacturing Base, Sales Area and Its Competitors

Table 224. YiChang HEC ChangJiang Pharmaceutical Antihyperuricemic Agents Product Offered

Table 225. YiChang HEC ChangJiang Pharmaceutical Antihyperuricemic Agents Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2020-2022)

Table 226. YiChang HEC ChangJiang Pharmaceutical Main Business

Table 227. YiChang HEC ChangJiang Pharmaceutical Latest Developments

Table 228. KPC Pharmaceuticals Basic Information, Antihyperuricemic Agents Manufacturing Base, Sales Area and Its Competitors

Table 229. KPC Pharmaceuticals Antihyperuricemic Agents Product Offered

Table 230. KPC Pharmaceuticals Antihyperuricemic Agents Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2020-2022)

Table 231. KPC Pharmaceuticals Main Business

Table 232. KPC Pharmaceuticals Latest Developments

Table 233. Tonghua Limin Basic Information, Antihyperuricemic Agents Manufacturing Base, Sales Area and Its Competitors

Table 234. Tonghua Limin Antihyperuricemic Agents Product Offered

Table 235. Tonghua Limin Antihyperuricemic Agents Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2020-2022)

Table 236. Tonghua Limin Main Business

Table 237. Tonghua Limin Latest Developments

Table 238. Beijing Jialin Pharmaceutical Basic Information, Antihyperuricemic Agents Manufacturing Base, Sales Area and Its Competitors

Table 239. Beijing Jialin Pharmaceutical Antihyperuricemic Agents Product Offered

Table 240. Beijing Jialin Pharmaceutical Antihyperuricemic Agents Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2020-2022)

Table 241. Beijing Jialin Pharmaceutical Main Business

Table 242. Beijing Jialin Pharmaceutical Latest Developments

List of Figures

Figure 1. Picture of Antihyperuricemic Agents

Figure 2. Antihyperuricemic Agents Report Years Considered

Figure 3. Research Objectives

Figure 4. Research Methodology

Figure 5. Research Process and Data Source

Figure 6. Global Antihyperuricemic Agents Sales Growth Rate 2017-2028 (K Units)

Figure 7. Global Antihyperuricemic Agents Revenue Growth Rate 2017-2028 ($ Millions)

Figure 8. Antihyperuricemic Agents Sales by Region (2021 & 2028) & ($ millions)

Figure 9. Product Picture of Inhibit Uric Acid Production Agents

Figure 10. Product Picture of Promote Uric Acid Excretion Agents

Figure 11. Product Picture of Others

Figure 12. Global Antihyperuricemic Agents Sales Market Share by Type in 2021

Figure 13. Global Antihyperuricemic Agents Revenue Market Share by Type (2017-2022)

Figure 14. Antihyperuricemic Agents Consumed in Hospital Pharmacies

Figure 15. Global Antihyperuricemic Agents Market: Hospital Pharmacies (2017-2022) & (K Units)

Figure 16. Antihyperuricemic Agents Consumed in Retail Pharmacies

Figure 17. Global Antihyperuricemic Agents Market: Retail Pharmacies (2017-2022) & (K Units)

Figure 18. Antihyperuricemic Agents Consumed in Online Pharmacies

Figure 19. Global Antihyperuricemic Agents Market: Online Pharmacies (2017-2022) & (K Units)

Figure 20. Global Antihyperuricemic Agents Sales Market Share by Distribution Channel (2017-2022)

Figure 21. Global Antihyperuricemic Agents Revenue Market Share by Distribution Channel in 2021

Figure 22. Antihyperuricemic Agents Revenue Market by Company in 2021 ($ Million)

Figure 23. Global Antihyperuricemic Agents Revenue Market Share by Company in 2021

Figure 24. Global Antihyperuricemic Agents Sales Market Share by Geographic Region (2017-2022)

Figure 25. Global Antihyperuricemic Agents Revenue Market Share by Geographic Region in 2021

Figure 26. Global Antihyperuricemic Agents Sales Market Share by Region (2017-2022)

Figure 27. Global Antihyperuricemic Agents Revenue Market Share by Country/Region in 2021

Figure 28. Americas Antihyperuricemic Agents Sales 2017-2022 (K Units)

Figure 29. Americas Antihyperuricemic Agents Revenue 2017-2022 ($ Millions)

Figure 30. APAC Antihyperuricemic Agents Sales 2017-2022 (K Units)

Figure 31. APAC Antihyperuricemic Agents Revenue 2017-2022 ($ Millions)

Figure 32. Europe Antihyperuricemic Agents Sales 2017-2022 (K Units)

Figure 33. Europe Antihyperuricemic Agents Revenue 2017-2022 ($ Millions)

Figure 34. Middle East & Africa Antihyperuricemic Agents Sales 2017-2022 (K Units)

Figure 35. Middle East & Africa Antihyperuricemic Agents Revenue 2017-2022 ($ Millions)

Figure 36. Americas Antihyperuricemic Agents Sales Market Share by Country in 2021

Figure 37. Americas Antihyperuricemic Agents Revenue Market Share by Country in 2021

Figure 38. United States Antihyperuricemic Agents Revenue Growth 2017-2022 ($ Millions)

Figure 39. Canada Antihyperuricemic Agents Revenue Growth 2017-2022 ($ Millions)

Figure 40. Mexico Antihyperuricemic Agents Revenue Growth 2017-2022 ($ Millions)

Figure 41. Brazil Antihyperuricemic Agents Revenue Growth 2017-2022 ($ Millions)

Figure 42. APAC Antihyperuricemic Agents Sales Market Share by Region in 2021

Figure 43. APAC Antihyperuricemic Agents Revenue Market Share by Regions in 2021

Figure 44. China Antihyperuricemic Agents Revenue Growth 2017-2022 ($ Millions)

Figure 45. Japan Antihyperuricemic Agents Revenue Growth 2017-2022 ($ Millions)

Figure 46. South Korea Antihyperuricemic Agents Revenue Growth 2017-2022 ($ Millions)

Figure 47. Southeast Asia Antihyperuricemic Agents Revenue Growth 2017-2022 ($ Millions)

Figure 48. India Antihyperuricemic Agents Revenue Growth 2017-2022 ($ Millions)

Figure 49. Australia Antihyperuricemic Agents Revenue Growth 2017-2022 ($ Millions)

Figure 50. Europe Antihyperuricemic Agents Sales Market Share by Country in 2021

Figure 51. Europe Antihyperuricemic Agents Revenue Market Share by Country in 2021

Figure 52. Germany Antihyperuricemic Agents Revenue Growth 2017-2022 ($ Millions)

Figure 53. France Antihyperuricemic Agents Revenue Growth 2017-2022 ($ Millions)

Figure 54. UK Antihyperuricemic Agents Revenue Growth 2017-2022 ($ Millions)

Figure 55. Italy Antihyperuricemic Agents Revenue Growth 2017-2022 ($ Millions)

Figure 56. Russia Antihyperuricemic Agents Revenue Growth 2017-2022 ($ Millions)

Figure 57. Middle East & Africa Antihyperuricemic Agents Sales Market Share by Country in 2021

Figure 58. Middle East & Africa Antihyperuricemic Agents Revenue Market Share by Country in 2021

Figure 59. Egypt Antihyperuricemic Agents Revenue Growth 2017-2022 ($ Millions)

Figure 60. South Africa Antihyperuricemic Agents Revenue Growth 2017-2022 ($ Millions)

Figure 61. Israel Antihyperuricemic Agents Revenue Growth 2017-2022 ($ Millions)

Figure 62. Turkey Antihyperuricemic Agents Revenue Growth 2017-2022 ($ Millions)

Figure 63. GCC Country Antihyperuricemic Agents Revenue Growth 2017-2022 ($ Millions)

Figure 64. Manufacturing Cost Structure Analysis of Antihyperuricemic Agents in 2021

Figure 65. Manufacturing Process Analysis of Antihyperuricemic Agents

Figure 66. Industry Chain Structure of Antihyperuricemic Agents

Figure 67. Channels of Distribution

Figure 68. Distributors Profiles